Latest Stock Market News

The stock quoted a 52-week high price of Rs 1356.9 and low of Rs 918.0.

As per the red herring prospectus, 75 per cent of the issue will be reserved for qualified institutional investors, another 15 for non-institutional bidders and the rest for retail investors.

Denying the information, SEBI responded to RTI activist Subhash Agrawal that the information sought by him pertains to its internal functioning, and disclosure of which may hamper decision making in its supervisory and regulatory role.

On the technical charts, the RSI of the stock stood at 38.2.

The company said it has a global footprint through a sales office in the United States of America and a procurement office in China and has supplied solar PV modules to customers in 32 countries, as of December 31, 2021.

According to the brokerage, the bank’s higher retail orientation and steady improvement in risk-adjusted returns call for a sustained re-rating.

“We are into MNC pharma companies like Abbot Laboratories. After the correction, we have also started to buy into Dr Lal Path Labs, a company with 35-40% ROEs, a company which has a larger market share of around Rs 800 revenues per patient. These are some metrics which we like. Apart from it, we also like the CRAM space, where Syngene has been one of the top picks in the last two, three years.”

A total of 9,559 shares changed hands on the counter till 12:48PM (IST).

The stock quoted a 52-week high price of Rs 1823.0 and low of Rs 1375.55.

Nithin Kamath asked investors to check if they have realised short-term capital gains on which they are required to pay 15 per cent tax.